cullen/frost banker inc buy pt larg provis base oil maintain ep estim
rais valuat target pt analyst michael diana full summari
inc hold even comp hiv get tough remdesivir promis covid patient
reason buy maintain hold analyst jason mccarthi ph full summari
inc hold pt reduc estim base lower order downturn maintain hold
delay rebound order commerci custom analyst tate sullivan cfa full summari
vike inc buy pt strong balanc sheet posit vike weather covid storm
soligenix inc sngx buy pt one go cycl phase flash trial posit analyst jason
biocardia inc bcda buy pt phase cardiamp trial get endpoint modif trial remain track
pluristem inc psti buy pt non-dilut financ agreement eu watch
addit data plx cell covid analyst jason mccarthi ph full summari
corpor event pleas contact maxim salesperson inform
maxim group infecti diseas virtual confer host mccarthi vendetti tue may
even comp hiv get tough remdesivir
promis covid patient reason buy
gilead report product revenu y/i
sequenti beat consensu note revenu includ
earli refil patient weather covid storm
non-gaap ep note non-gaap ep longer regularli
exclud stock base compens beat consensu non-gaap
net incom flat y/i sequenti although note
neg impact one time charg mainli hcv-relat
inventori writedown gilead end year cash
growth come hiv franchis gilead flagship
top antiretrovir market continu
drive doubl digit y/i growth becom challeng much like saw
hcv franchis gilead may becom victim success
gilead late stage busi develop pipelin includ galapago
glpg nr partnership forti seven acquisit potenti
promis though timelin trial approv launch activ may
slow nonetheless still area look gilead potenti
return growth view cours also await
posit remdesivir remain promis
therapeut could potenti game changer pandem
howev unlik growth driver gilead remdesivir
approv seem like outcom revenu
could help partial off-set lost revenu due covid delay pipelin
sale approv drug maintain hold
commerci updat hcv revenu y/i
sequenti one contributor sequenti increas posit season effect
hcv continu look stabl predict posit hiv
franchis continu post y/i growth sale y/i though
sequenti season effect cite contributor import
note much earli purchas came hiv drug make
sens consid vulner popul biktarvi remain
regimen across patient group us eu though note
non-gilead hiv drug enter top prescrib regimen us eu
gilead still hold top us eu especi among switch
naiv patient could indic increas adopt competitor though
could also relat cannib franchis biktarvi compani
also work convert prep descovi prep patient descovi vs
truvada yescarta revenu sequenti though expect
impact bristol myer nr lawsuit april result gilead
owe damag royalti yescarta sale substanti
neg prospect gilead car-t franchis
impact manag comment guidanc although compani
discuss expect surround impact busi
activ base case predic peak march-juli potenti return
fall/wint lower impact phase return normal recoveri
underway though demand fundament remain strong could
neg impact due reduc visit healthcar provid continu page
click full note
larg provis base oil maintain
ep estim rais valuat pt
net loss per share vs streetaccount consensu
credit loss provis vs streetaccount consensu
provis assum price oil
view scenario provis extrem
adequ cover futur loss especi problem energi loan
increas energi borrow ask deferr
maintain quarterli dividend repres yield
maintain ep estim lower provis expens
off-set lower nim rais price target due
higher valuat best-in-class smid-cap bank equat rais
ep estim in-line valuat bank
includ per share net non-recur gain vs
streetaccount consensu net interest margin nim narrow vs
less expect manag guid materi downward pressur
nim loan grew strong pipelin decreas
accord manag deposit growth solid core effici
ratio remain stabl due control expens
credit qualiti record out-performance credit downturn expect
time credit loss reserv equal loan
non-perform asset npa well strong capit ratio enter
downturn posit strength energi loan total loan
reserv energi loan problem loan
seven sector energi risk repres loan
carri reserv loan defer payment total
portfolio deferr equal view larg reserv
adequ cover futur loss
houston expans expens short term benefici long term plan
add branch houston date order increas market share
fourth largest citi manag expect absorb biggest impact
houston expans expect houston initi begin meaning
note largest lender houston market payrol
protect program ppp evid penetr market
maintain ep estim view credit loss provis
over-s attribut oil price scenario cecl current
expect credit loss requir life-of-loan provis larg reserv
provis much previous expect
also manag guid lower expens growth previous anticip
also lower nim expect lower provis expens off-set lower nim
page updat earn model
rais price target share current trade
ep estim new price target equat ep estim vs
previous due higher valuat best-in-class smid-cap bank sinc
begin report season bank
reiter buy rate next four quarter expect stock price
appreci price target dividend yield highest
among peer coverag result estim total
return view bank credibl abl
manag success downturn energi sector
click full note
reduc estim base lower order
downturn maintain hold delay rebound order
commerci custom
reduc ep
base lower order downturn new commerci construct
activ due
releas result yesterday pre- market preannounc
revenu ep last week
earn call yesterday indic strength data center
work low util level busi area due
repurchas share compar forecast
maintain hold rate base potenti order delay
reduc forecast base lower order amid downturn new
construct reduc order forecast due downturn new construct
activ amid continu busi work schedul strong
bid activ end market data center particular geographi
expect delay order particularli new construct
reduc estim revenu million million ep
base revenu mix weight hvac versu electr work
lower margin
lower ep estim remain consensu base resili margin
work schedul declin believ reduc employe prevent
collaps margin also continu win larg job exist facil
smaller competitor track record scale compet
view exposur multipl end market includ govern facil
infrastructur support margin downturn result lower ep estim
remain consensu lower ep reduc
current consensu per thomson reuter note consensu
mean five analyst captur wide rang estim also
ep reduc consensu rang
although ep
also remain consensu base growth remain
perform oblig remain perform oblig rpo
proxi backlog increas y/i q/q billion
billion forecast addit grow rpo oper margin four
five report segment increas y/i total oper margin
decreas slightli prior year due revenu
lower-margin segment pre-announce last week report yesterday pre-market
open revenu billion rose y/i ep rose
y/i time pre-releas last week revenu match consensu ep
consensu due higher margin lower share repurchas
repurchas share compar forecast
forecast maintain quarterli dividend repurchas share
later year end cash debt
expect gener free cash flow last nine month
temporari disrupt work schedul base cost-cut gener profit
on-going project result forecast increas cash end
year compar debt
maintain hold rate price target share current trade
revis ep forecast base price target
current share price ep estim
previous base price target prior ep estim
slightli increas price target multipl base rpo growth
expect market-wid volatil continu near-term maintain hold
rate base potenti order delay commerci custom
estim repres revenu
compani overview instal maintain infrastructur insid larg
commerci build data center factori govern facil among other
infrastructur includ system distribut air condit electr heat
click full note
strong balanc sheet posit vike weather
vike therapeut report net loss end
period cash balanc sheet
enrol voyag studi current on-going expect
finish compani note delay surpris
compani indic said cash
vike balanc sheet suffici weather covid-rel
voyag addit ex-u site expect come on-line
addit data present year european associ
studi liver easl though event delay late
august due covid
vike also expect file ind thyroid receptor beta
tr agonist drug candid x-link adrenoleukodystrophi x-ald
trial follow
voyag studi current undergo studi
patient biopsy-confirm nash fibrosi score enrol
expect complet voyag studi includ patient higher
cardiovascular risk type diabet take lipid-low
medic like statin studi target enrol patient across five
treatment arm daili qd qd qod qod placebo
primari endpoint rel chang liver fat content via mri-pdff magnet
reson imag proton densiti fat fraction week secondari endpoint
includ biopsi evalu histolog chang fibrosi na score
watch nash space though see much covid delay
factor sever catalyst lay ahead signific pdufa
intercept nr ocaliva oca adcom meet
tent move june like attribut pandem first
nda file nash like set preced space includ defin market
payer dynam also watch genfit gnft- nr trial
data readout genfit ppar agonist expect though like
other space see timelin may impact covid
candid assess potenti use patient x-link
adrenoleukodystrophi x-ald diseas result accumul
long-chain fatti acid vlcfa due aberr peroxisom transport known
vlcfa accumul lead neuron neuromuscular toxic
preclin studi x-ald mous model lack gene induc
signific reduct plasma vlcfa rang week
week vlcfa also reduc tissu includ liver
brain spinal cord drug initi aim adult x-ald could
use adjunct gene therapi compani expect file ind
phase trial expect initi
x-ald compani
click full note
one go cycl phase flash trial
soligenix announc posit result cycl flash trial
evalu patient cutan t-cell lymphoma ctcl
cycl patient placebo cycl
treat week follow week treatment/placebo
cycl
patient receiv total week respons rate
measur composit assess lesion score
cail nearli improv cycl
conclus cycl data build upon posit result observ cycl
week respons rate similar ctcl therapi requir
year treatment case cycl result six-month
post-treat follow-up data expect next
synthet hypericin topic appli treatment early-stag
ctcl cutan t-cell lymphoma lesion activ fluoresc light
hour later given activ fluoresc vs uv ultraviolet avoid
risk secondari malign melanoma occur
current avail therapi photodynam therapi depend uv
even dna-damag chemotherapi
flash studi double-blind flash trial evalu
set across center us center also contain lead kol
ctcl space patient random placebo trial consist
three treatment cycl week durat treatment administ
weekli first week respons determin end week
double-blind first cycl patient index lesion treat
placebo second cycl open-label index lesion treat
placebo arm switch patient evalu
patient receiv therapi total week includ cycl
remain patient receiv placebo six week follow
addit six week third cycl patient option
lesion treat addit follow-up major patient
agre continu option compon primari endpoint
percent patient achiev success respons treat lesion defin
overal reduct use composit assess lesion sever
cail score system across three index lesion cycl evalu visit
week compar total cail score baselin
flash cycl data six-week treatment cohort placebo cohort cycl
receiv addit six week treatment open-label cycl compon
flash trial patient treat twice week week
saw least reduct lesion base cail score system
compar placebo signific improv note
six-week treatment cohort well substanti potenti
efficaci treatment platform highlight cycl recal cycl
random either treatment arm placebo arm receiv
therapi six week patient treat achiev least
reduct lesion compar placebo group week
model updat soligenix report result net loss
end period cash balanc sheet exclud grant
sourc non-dilut capit compani continu receiv
click full note
phase cardiamp trial get endpoint modif
biocardia announc fda-recommend chang primari endpoint
on-going pivot trial cardiamp cell therapi heart failur
primari endpoint go forward outcom composit score base
three-tier finklestein schoendeld fs hierarch analysi
take-away fs establish analysi use major heart
failur studi power unaffect
three tier analysi describ signific
chang patient experienc non-fat major advers coronari
cerebrovascular event macc recov factor six-
minut walk distanc one-year followup
overal chang rel minor trial remain track date
patient enrol across activ center trial expect
enrol across center compani also award new
patent helix system local biotherapeut deliveri cell
heart
biocardia cardiamp-hf pivot trial ischem heart failur trial target
enrol patient nyha class ii hf left ventricular eject
fraction lvef similar popul mesoblast revascor trial
open-label roll-in period complet patient random
sham-control portion patient random treatment sham
evalu base primari endpoint composit score base
three-tier finkelstein-schoenfeld fs hierarch analysi tier start
seriou event caus death cardiac death transplant
lvad placement move non-fat major advers coronari
first seven day lastli minut walk distanc month data
demonstr increas baselin month
secondari endpoint qol self-assess improv point
baselin month left ventricular eject fraction month improv
compar favor data safety/futil interim readout posit
trial clear continu chang data monitor board
dmb clear trial continu plan second interim plan
top-line data expect compani also plan move allogen
cell therapi call cardiallo clinic trial expect initi
timelin could impact may subject chang
ip portfolio updat around helix biocardia announc issuanc
patent drug deliveri cathet attach tissu method
use new patent extend ip portfolio around helix system
cover use helicl needl deliveri system deflect guid cathet
remind helix biotherapeut deliveri system enabl local deliveri
cardiamp cell heart muscl incorpor compani helix
transendocardi deliveri cathet helix combin morph
deflect guid cathet helix advanc within morph guid
provid enhanc navig cathet within heart imag
left side display helix dual lumen inject cathet helic shape needl
distal end dual lumen compris contrast lumen discharg
base helix confirm engag posit needl well
therapeut lumen cardiamp cell discharg distal tip
helic needl anchor confirm
model updat biocardia report net loss cash
balanc compani file current work address
click full note
non-dilut financ agreement eu
watch addit data plx cell covid
israel innov author non-dilut fund
pluristem support develop pluristem allogen cell therapi
includ
remind plx cell platform allogen cell therapi deriv
placent cell treatment sever medic condit cell
platform subject later stage program critic limb ischemia hip
fractur acut radiat syndrom well earlier-stag program
intermitt claudic gvhd well other
plx cell recent demonstr earli posit data sever
patient icu ventil stage diseas
patient acut respiratori distress syndrom ard may
respons cell therapi like plx cell given inher abil stem
cell act immun modul addit updat expect
non-dilut financ european invest bank announc
term agreement pluristem receiv
deploy three tranch first tranch consist financ
secur payabl eib singl payment follow five
year disburs first second tranch two annual payment
start fourth year disburs third tranch tranch
interest rate eib entitl receiv royalti futur
revenu period seven year start rate pro-rat
amount pluristem receiv financ
pluristem differenti product
capabl plx-pad stem cell administ without need hla-
match work increas decreas concentr certain bioactiv
molecul increas angiogenesi vegf angiogenin angiopoietin
reduc inflamm via promot muscl regener
osteopontin overal view pluristem plx cell pad
placental-deriv differ area/loc cultur condit
differenti moa manufactur process import note pluristem
own manufactur process state-of-the-art facil
produc compani cell therapi product commerci scale
plx cell subject on-going studi critic limb ischemia
interim data eu expect trial target
enrol complet enrol expect june though see
impact covid interim data expect could support condit approv
eu full data expect use support file us
approv primari endpoint time event death amput vs placebo
plx cell pipelin includ hip fractur recoveri plx cell
administ hip fractur surgeri expect total enrol
eu singl pivot trial need support file approv us fda
plan decid upon data top-line data expect though timelin may
shift due covid view also watch program acut
radiat syndrom ar develop fda anim rule well
program intermitt claudic graft vs host diseas earlier stage
plx cell alreadi demonstr earli signal efficaci
continu safeti sever patient acut respiratori
distress syndrom ard earli april data releas plx cell therapi result
patient surviv patient icu ventil
time six patient complet one week followup four experienc
improv respiratori paramet three six advanc stage wean
ventil posit signal plx cell though note previous still
small n-valu similar data announc allogen cell therapi
capricor capr buy also demonstr surviv
ard patient see capr note yesterday link cell therapi
differ allogen view data set
support one anoth demonstr potenti cell therapi
treat ard categori also mesoblast meso buy
nr studi underway pluristem alreadi dose us patient
compassion use program announc addit updat psti
other space around expect
click full note
maxim analyst coverag univers
sector coverag
care well
receiv full disclosur compani maxim group coverag mention report pleas send
